Triggering receptor expressed on myeloid cells 2 (TREM2) was recently highlighted as a novel immune suppressive marker in peripheral tumors. The aim of this study was to characterize expression in gliomas and investigate its contribution in glioma progression by using mouse line. Our results showed that higher expression was correlated with poor prognosis in glioma patients. Unexpectedly, TREM2 deficiency did not have a beneficial effect in a pre-clinical model of glioma. The increased expression in glioma was likely due to increased myeloid cell infiltration, as evidenced by our single-cell analysis showing that almost all microglia and macrophages in gliomas were TREM2. Furthermore, we found that deficiency of TREM2 impaired tumor-myeloid phagocytosis and MHCII presentation, and significantly reduced CD4 T cells in tumor hemispheres. Our results revealed a previously unrecognized protective role of tumor-myeloid TREM2 in promoting MHCII-associated CD4 T cell response against gliomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104080 | PMC |
| http://dx.doi.org/10.1101/2023.04.05.535697 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.
Neuro Oncol
May 2024
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Background: Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors.
View Article and Find Full Text PDFTREM2 mediates MHCII-associated CD4 T cell response against gliomas.
bioRxiv
April 2023
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Triggering receptor expressed on myeloid cells 2 (TREM2) was recently highlighted as a novel immune suppressive marker in peripheral tumors. The aim of this study was to characterize expression in gliomas and investigate its contribution in glioma progression by using mouse line. Our results showed that higher expression was correlated with poor prognosis in glioma patients.
View Article and Find Full Text PDFIdentifying immunodominant T cell epitopes remains a significant challenge in the context of infectious disease, autoimmunity, and immuno-oncology. To address the challenge of antigen discovery, we developed a quantitative proteomic approach that enabled unbiased identification of major histocompatibility complex class II (MHCII)-associated peptide epitopes and biochemical features of antigenicity. On the basis of these data, we trained a deep neural network model for genome-scale predictions of immunodominant MHCII-restricted epitopes.
View Article and Find Full Text PDFChemical and genetic control of IFNγ-induced MHCII expression.
EMBO Rep
September 2018
Department of Cell and Chemical Biology, LUMC, Leiden, The Netherlands
The cytokine interferon-γ (IFNγ) can induce expression of MHC class II (MHCII) on many different cell types, leading to antigen presentation to CD4 T cells and immune activation. This has also been linked to anti-tumour immunity and graft-versus-host disease. The extent of MHCII upregulation by IFNγ is cell type-dependent and under extensive control of epigenetic regulators and signalling pathways.
View Article and Find Full Text PDFLarge adipocytes function as antigen-presenting cells to activate CD4(+) T cells via upregulating MHCII in obesity.
Int J Obes (Lond)
January 2016
Key Laboratory of Metabolic Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, Fudan University Basic Medical School, Shanghai, PR China.
Background/objectives: Although obesity is associated with low-grade inflammation and metabolic disorders, clinical studies suggested some obese people were metabolically healthy with smaller adipocyte size compared with metabolically abnormal obese (MAO). This indicated adipocyte size may be an important predictor underlay the distinction between MAO and metabolically healthy obese. As recent study has shown that adipocytes expressed class II major histocompatibility complex (MHCII), which functioned as APCs during obesity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!